CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Official Title

Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Brief Summary

      The purpose of this study is to determine if it is possible to give CPI-613 with the drug
      Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this
      study will also test the safety of CPI-613 when given in combination with Bendamustine.

Detailed Description

      Primary Objectives: A pilot Study to evaluate the feasibility, safety and tolerability of a
      two day course per cycle of Bendamustine plus CPI-613 in patients with relapsed and
      refractory T cell non-hodgkin lymphoma.

      Exploratory Objectives

      To evaluate:

        -  Overall response rate (ORR) and disease control rate (DCR) derived from the Lugano

        -  Duration of response (DOR) derived from the Lugano classification.

        -  Progression-Free-Survival (PFS) derived from Lugano classification.

        -  Overall Survival (OS).

        -  Single cell transcriptomics from PMBCs pre- and post-treatment; for correlative analyses
           of blood PBMC (and possibly excess pre-treatment tumor biopsy) cell population diversity
           and functional states to reveal potential mechanisms of drug treatment with regard to
           patient response status.

Study Phase

Phase 2

Study Type


Primary Outcome

Number of Participants To Successfully Complete Therapy Regimen

Secondary Outcome

 Overall Response Rate


Relapsed T-Cell Lymphoma


CPI 613

Study Arms / Comparison Groups

 CPI-613 in Combination with Bendamustine
Description:  CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 16, 2020

Completion Date

June 2025

Primary Completion Date

September 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must meet all of the following inclusion criteria before enrollment:

          -  Histologically or cytologically confirmed PTCL (all subtypes) or CTCL (mycosis
             fungoides/Sezary syndrome) as defined by 2016 World Health Organization (WHO)

        For patients with PTCL:

          -  Patients must have relapsed/refractory disease to one or more systemic therapies.

          -  Patients with CD30-positive lymphoma must have received, be ineligible for, or
             intolerant to brentuximab vedotin.

          -  Patients with limited prior exposure to Bendamustine (less than 2 full cycles or ≤ 480
             mg/m2) may be included, based on PI discretion.

          -  Patients must have measurable disease (e.g., a tumor mass >1 cm or evidence of bone
             marrow involvement).

        For patients with CTCL, Stage IB-IVB mycosis fungoides or Sezary syndrome are eligible

          -  Patients must have relapsed/refractory disease to at least one previous systemic
             therapy. Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a
             systemic therapy.

          -  Male and female patients 18 years of age and older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  Expected survival greater than 3 months.

          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must use accepted contraceptive methods (abstinence, intrauterine device
             [IUD], oral contraceptive or double barrier device) during the study, and must have a
             negative serum or urine pregnancy test within 1 week prior to treatment initiation.

          -  Fertile men must practice effective contraceptive methods during the study, unless
             documentation of infertility exists.

          -  At least 2 weeks must have elapsed from prior chemotherapy drugs (other than steroids)
             or radiation

          -  At least 6 weeks must have elapsed from prior autologous stem cell transplant and 12
             weeks must have elapsed from prior allogeneic stem cell transplant.

          -  Laboratory values ≤2 weeks must be: Adequate hematological function (absolute
             neutrophil count [ANC] ≥1,500/mm3, platelets ≥100,000/mm3). In subjects with known
             bone marrow involvement, ANC must be ≥ 1000/mm3 and platelets ≥75,000/mm3; Adequate
             hepatic function (aspartate aminotransferase [AST/SGOT] less than or equal to 3x upper
             normal limit [UNL], alanine aminotransferase [ALT/SGPT] less than or equal to 3x UNL
             (≤5x UNL if liver metastases present), bilirubin less than or equal to 1.5x UNL);
             Adequate renal function (serum creatinine less than or equal to 1.5 mg/dL or 133

          -  No evidence of current infection.

          -  Mentally competent, ability to understand and willingness to sign the informed consent

        Exclusion Criteria:

          -  Patients with the following characteristics are excluded:

          -  Known cerebral metastases, central nervous system (CNS) or epidural tumor.

          -  History of prior malignancy and considered to be at greater than 30% risk of relapse

          -  Patients receiving any other standard or investigational treatment for their cancer,
             or any other investigational agent for any indication, within the past 2 weeks prior
             to initiation of treatment with study drugs (steroids are allowed)

          -  Patients with a history of allogeneic transplant must not have ≥ grade 3
             graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic

          -  Serious medical illness that would potentially increase patients' risk for toxicity.

          -  Pregnant women, or women of child-bearing potential not using reliable means of
             contraception (because the teratogenic potential of CPI-613 is unknown).

          -  Lactating females.

          -  Fertile men unwilling to practice contraceptive methods during the study period.

          -  Any condition or abnormality which may, in the opinion of the investigator, compromise
             the safety of patients.

          -  Unwilling or unable to follow protocol requirements.

          -  Active heart disease including but not limited to symptomatic congestive heart
             failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic
             myocardial infarction or symptomatic congestive heart failure.

          -  Evidence of current infection..

          -  Patients with known HIV infection, hepatitis B, or hepatitis C with positive viral

          -  Patients who have received cancer immunotherapy of any type within the past 2 weeks
             prior to initiation of CPI-613 treatment.




18 Years - N/A

Accepts Healthy Volunteers



Rakhee Vaidya, M.B.B.S., 336-716-5440, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs

WFBCCC 28419

Responsible Party


Study Sponsor

Wake Forest University Health Sciences


 National Cancer Institute (NCI)

Study Sponsor

Rakhee Vaidya, M.B.B.S., Principal Investigator, Wake Forest University Health Sciences

Verification Date

May 2022